Transthyretin Amyloidosis Treatment Market Size to Reach USD 3.2 Billion by 2032 Global Transthyretin Amyloidosis (ATTR) treatment market is undergoing a rapid transformation as breakthroughs in gene-silencing therapies, improved diagnostics, and expanded access to specialty care reshape outcomes for patients with this rare and life-threatening disease. Valued at approximately USD 1.5 billion in 2024, the market is forecast to reach USD 3.2 billion by 2032, expanding at a robust CAGR of over 10%. This sustained growth reflects rising disease recognition, accelerated therapeutic innovation, and increasing investment in orphan and precision medicines worldwide. Access the complete report https://www.24lifesciences.com/transthyretin-amyloidosis-treatment-market-9759